Wellington Management Group LLP Has $38.48 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Wellington Management Group LLP lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 29.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 533,710 shares of the medical equipment provider's stock after selling 220,542 shares during the quarter. Wellington Management Group LLP owned about 0.24% of Hologic worth $38,475,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of HOLX. Public Sector Pension Investment Board increased its holdings in shares of Hologic by 13.7% during the 3rd quarter. Public Sector Pension Investment Board now owns 9,959 shares of the medical equipment provider's stock worth $811,000 after purchasing an additional 1,200 shares during the period. HighTower Advisors LLC grew its position in Hologic by 9.8% during the third quarter. HighTower Advisors LLC now owns 22,603 shares of the medical equipment provider's stock worth $1,832,000 after buying an additional 2,012 shares in the last quarter. Janus Henderson Group PLC increased its stake in Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider's stock valued at $2,344,000 after acquiring an additional 800 shares during the period. Quantinno Capital Management LP boosted its position in Hologic by 10.9% in the third quarter. Quantinno Capital Management LP now owns 41,424 shares of the medical equipment provider's stock valued at $3,374,000 after buying an additional 4,063 shares in the last quarter. Finally, Stifel Financial Corp grew its stake in Hologic by 115.8% during the third quarter. Stifel Financial Corp now owns 20,354 shares of the medical equipment provider's stock worth $1,658,000 after buying an additional 10,924 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Remove Ads

Hologic Trading Up 1.2 %

NASDAQ:HOLX traded up $0.69 on Friday, reaching $57.85. The company's stock had a trading volume of 4,235,273 shares, compared to its average volume of 1,909,933. Hologic, Inc. has a 1-year low of $56.27 and a 1-year high of $84.67. The business's 50-day moving average price is $62.47 and its two-hundred day moving average price is $71.55. The firm has a market cap of $12.98 billion, a PE ratio of 18.25, a PEG ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HOLX. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Wolfe Research initiated coverage on Hologic in a research note on Friday, December 13th. They issued a "peer perform" rating on the stock. Morgan Stanley reduced their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. William Blair reissued an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Finally, Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of "Hold" and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.